- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01940770
Specific Clinical Experience Investigation for Long-term Use of Bydureon.
Specific Clinical Experience Investigation for Long-term Use of Bydureon Subcutaneous Injection 2 mg and Bydureon Subcutaneous Injection 2 mg PEN
Aperçu de l'étude
Statut
Les conditions
Description détaillée
To confirm the safety and efficacy of Bydureon (hereinafter referred to as Bydureon) in long-term use in Japanese patients with type 2 diabetes mellitus under actual drug use.
- Primary Objective To confirm the safety profile in Japanese patients with type 2 diabetes mellitus receiving Bydureon under daily practices.
Secondary objective As the secondary objective of this S-CEI, the following items are to be investigated.
- Frequencies of AEs related to cardiovascular events, hypoglycaemia, digestive symptoms, and injection site reaction.
- Development of pancreatitis, renal impairment (especially acute renal failure), hypersensitivity reaction, and malignant tumour (especially thyroid tumour and pancreatic malignancy)
- Safety in patients with mild or moderate renal impairment
- Changes of weight, blood pressure, pulse rate, fasting blood sugar, fasting insulin, HbA1c, and blood lipids
- Bydureon administration under daily practices focusing on the patient's demographics and clinical characteristics of diabetes mellitus (duration of diabetes mellitus, treatment duration, complications, Bydureon administration, etc)
- Anti-exenatide antibody titer in AE cases (hypersensitivity, loss of control of blood sugar)
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Aichi, Japon, D5551C00001
- Research Site
-
Akita, Japon, D5551C00001
- Research Site
-
Aomori, Japon, D5551C00001
- Research Site
-
Chiba, Japon, D5551C00001
- Research Site
-
Ehime, Japon, D5551C00001
- Research Site
-
Fukui, Japon, D5551C00001
- Research Site
-
Fukuoka, Japon, D5551C00001
- Research Site
-
Fukushima, Japon, D5551C00001
- Research Site
-
Gifu, Japon, D5551C00001
- Research Site
-
Gunma, Japon, D5551C00001
- Research Site
-
Hiroshima, Japon, D5551C00001
- Research Site
-
Hokkaido, Japon, D5551C00001
- Research Site
-
Hyogo, Japon, D5551C00001
- Research Site
-
Ibaraki, Japon, D5551C00001
- Research Site
-
Ishikawa, Japon, D5551C00001
- Research Site
-
Iwate, Japon, D5551C00001
- Research Site
-
Kagawa, Japon, D5551C00001
- Research Site
-
Kagoshima, Japon, D5551C00001
- Research Site
-
Kanagawa, Japon, D5551C00001
- Research Site
-
Kochi, Japon, D5551C00001
- Research Site
-
Kumamoto, Japon, D5551C00001
- Research Site
-
Kyoto, Japon, D5551C00001
- Research Site
-
Mie, Japon, D5551C00001
- Research Site
-
Miyagi, Japon, D5551C00001
- Research Site
-
Miyazaki, Japon, D5551C00001
- Research Site
-
Nagano, Japon, D5551C00001
- Research Site
-
Nagasaki, Japon, D5551C00001
- Research Site
-
Nara, Japon, D5551C00001
- Research Site
-
Niigata, Japon, D5551C00001
- Research Site
-
Oita, Japon, D5551C00001
- Research Site
-
Okayama, Japon, D5551C00001
- Research Site
-
Okinawa, Japon, D5551C00001
- Research Site
-
Osaka, Japon, D5551C00001
- Research Site
-
Saga, Japon, D5551C00001
- Research Site
-
Saitama, Japon, D5551C00001
- Research Site
-
Shiga, Japon, D5551C00001
- Research Site
-
Shimane, Japon, D5551C00001
- Research Site
-
Shizuoka, Japon, D5551C00001
- Research Site
-
Tochigi, Japon, D5551C00001
- Research Site
-
Tokushima, Japon, D5551C00001
- Research Site
-
Tokyo, Japon, D5551C00001
- Research Site
-
Tottori, Japon, D5551C00001
- Research Site
-
Toyama, Japon, D5551C00001
- Research Site
-
Wakayama, Japon, D5551C00001
- Research Site
-
Yamagata, Japon, D5551C00001
- Research Site
-
Yamaguchi, Japon, D5551C00001
- Research Site
-
Yamanashi, Japon, D5551C00001
- Research Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- The patients with type 2 diabetes mellitus who inadequately respond to sulfonylurea, biuguanides, and/or thiazolidines (monotherapy or combination use) in addition to diet and exercise.
Exclusion Criteria:
- No past history of hypersensitivity to the components of Bydureon.
- Not the patient with diabetic ketoacidosis, diabetic coma/ precoma, and/ or type 1 diabetes mellitus.
- Bydureon will not be administered to the patient in an emergency situation such as severe infection and operation.
- Not the patient with severe renal impairment, including those receiving dialysis.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Adverse event incidence
Délai: 3 years
|
Number of Adverse Drug Reactions
|
3 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Mean change of HbA1c
Délai: from baseline up to 3 years
|
Change value of HbA1c from baseline as mean.
|
from baseline up to 3 years
|
Mean change of weight
Délai: from baseline up to 3 years
|
Change value of weight from baseline as mean.
|
from baseline up to 3 years
|
Mean change of blood pressure
Délai: from baseline up to 3 years
|
Change value of blood pressure from baseline as mean.
|
from baseline up to 3 years
|
Mean change of lipid metabolism
Délai: from baseline up to 3 years
|
Change value of lipid metabolism from baseline as mean.
|
from baseline up to 3 years
|
Mean change of HbA1c
Délai: from baseline up to 3 years
|
Change value of HbA1c from baseline as median.
|
from baseline up to 3 years
|
Mean change of HbA1c
Délai: from baseline up to 3 years
|
Change value of HbA1c from baseline as minimum.
|
from baseline up to 3 years
|
Mean change of HbA1c
Délai: from baseline up to 3 years
|
Change value of HbA1c from baseline as max.
|
from baseline up to 3 years
|
Mean change of weight
Délai: from baseline up to 3 years
|
Change value of weight from baseline as median.
|
from baseline up to 3 years
|
Mean change of weight
Délai: from baseline up to 3 years
|
Change value of weight from baseline as minimum.
|
from baseline up to 3 years
|
Mean change of weight
Délai: from baseline up to 3 years
|
Change value of weight from baseline as max.
|
from baseline up to 3 years
|
Mean change of blood pressure
Délai: from baseline up to 3 years
|
Change value of blood pressure from baseline as median.
|
from baseline up to 3 years
|
Mean change of blood pressure
Délai: from baseline up to 3 years
|
Change value of blood pressure from baseline as minimum.
|
from baseline up to 3 years
|
Mean change of blood pressure
Délai: from baseline up to 3 years
|
Change value of blood pressure from baseline as max.
|
from baseline up to 3 years
|
Mean change of lipid metabolism
Délai: from baseline up to 3 years
|
Change value of lipid metabolism from baseline as median.
|
from baseline up to 3 years
|
Mean change of lipid metabolism
Délai: from baseline up to 3 years
|
Change value of lipid metabolism from baseline as minimum.
|
from baseline up to 3 years
|
Mean change of lipid metabolism
Délai: from baseline up to 3 years
|
Change value of lipid metabolism from baseline as max.
|
from baseline up to 3 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Shigeru Yoshida, MD, Quality & Safety Compliance Office
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- D5551C00001
- EUPAS18608 (Identificateur de registre: ENCePP)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Diabète de type 2
-
Bnai Zion Medical CenterInconnue
-
Jiangsu HengRui Medicine Co., Ltd.Complété
-
HighTide Biopharma Pty LtdRecrutement
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Pas encore de recrutement
-
Endogenex, Inc.Pas encore de recrutementDiabète sucré, Type 2 | Diabète | Diabète sucré de type 2 | Diabète de type 2 | Diabète de type 2
-
Jeil Pharmaceutical Co., Ltd.Pas encore de recrutementDiabète sucré de type 2Corée, République de
-
Nanjing First Hospital, Nanjing Medical UniversityRecrutement
-
Nanjing First Hospital, Nanjing Medical UniversityRecrutement
-
Xiangya Hospital of Central South UniversityRecrutement
-
Sun Yat-sen UniversityThe First Affiliated Hospital with Nanjing Medical University; Guangdong Provincial... et autres collaborateursComplété